诺爱药业

Nuoyai Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of next-generation small molecule targeted therapies for oncology. The company's research focus is primarily on overcoming drug resistance in cancer, with a lead candidate, NY-101, targeting the EGFR C797S mutation in non-small cell lung cancer. Nuoyai's pipeline also includes inhibitors for KRAS G12C, SHP2, and FGFR, aiming to provide effective treatments for patients with limited options. The firm is backed by prominent life science investors and maintains research facilities in both Hangzhou and Shanghai. Through its proprietary discovery platform, Nuoyai continues to advance a portfolio of high-potential candidates toward clinical validation.